These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
280 related articles for article (PubMed ID: 16228280)
1. Efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of sarcoptic mange and otoacariosis in dogs: results af a European field study. Krieger K; Heine J; Dumont P; Hellmann K Parasitol Res; 2005 Oct; 97 Suppl 1():S81-S88. PubMed ID: 16228280 [TBL] [Abstract][Full Text] [Related]
2. Clinical evaluation of the safety and efficacy of 10% imidacloprid + 2.5% moxidectin topical solution for the treatment of ear mite (Otodectes cynotis) infestations in dogs. Arther RG; Davis WL; Jacobsen JA; Lewis VA; Settje TL Vet Parasitol; 2015 May; 210(1-2):64-8. PubMed ID: 25801226 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of a combination of selamectin plus sarolaner for the treatment and prevention of flea infestations and the treatment of ear mites in cats presented as veterinary patients in the United States. Vatta AF; Myers MR; Rugg JJ; Chapin S; Pullins A; King VL; Rugg D Vet Parasitol; 2019 Jun; 270 Suppl 1():S3-S11. PubMed ID: 30579753 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the efficacy and safety of imidacloprid 10% plus moxidectin 2.5% spot-on in the treatment of generalized demodicosis in dogs: results of a European field study. Heine J; Krieger K; Dumont P; Hellmann K Parasitol Res; 2005 Oct; 97 Suppl 1():S89-S96. PubMed ID: 16228281 [TBL] [Abstract][Full Text] [Related]
5. The efficacy of an imidacloprid/moxidectin combination against naturally acquired Sarcoptes scabiei infestations on dogs. Fourie LJ; Heine J; Horak IG Aust Vet J; 2006; 84(1-2):17-21. PubMed ID: 16498829 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of the combination imidacloprid 10 % / moxidectin 1.0 % spot-on (Advocate(®) spot-on for small cats and ferrets) in the treatment of ear mite infection (Otodectes cynotis) in ferrets. Le Sueur C; Bour S; Schaper R Parasitol Res; 2011 Aug; 109 Suppl 1():S149-56. PubMed ID: 21739384 [TBL] [Abstract][Full Text] [Related]
7. Canine generalized demodicosis treated with varying doses of a 2.5% moxidectin+10% imidacloprid spot-on and oral ivermectin: parasiticidal effects and long-term treatment outcomes. Paterson TE; Halliwell RE; Fields PJ; Louw ML; Ball G; Louw J; Pinckney R Vet Parasitol; 2014 Oct; 205(3-4):687-96. PubMed ID: 25262617 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of orally administered fluralaner (Bravecto™) or topically applied imidacloprid/moxidectin (Advocate®) against generalized demodicosis in dogs. Fourie JJ; Liebenberg JE; Horak IG; Taenzler J; Heckeroth AR; Frénais R Parasit Vectors; 2015 Mar; 8():187. PubMed ID: 25881320 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a new spot-on formulation of selamectin plus sarolaner in the treatment of naturally occurring flea and tick infestations in cats presented as veterinary patients in Europe. Geurden T; Becskei C; Farkas R; Lin D; Rugg D Vet Parasitol; 2017 Apr; 238 Suppl 1():S12-S17. PubMed ID: 28395750 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of topically administered fluralaner or imidacloprid/moxidectin on dogs with generalised demodicosis. Fourie JJ; Meyer L; Thomas E Parasit Vectors; 2019 Jan; 12(1):59. PubMed ID: 30683143 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of imidacloprid 10 per cent/moxidectin 2-5 per cent spot-on in the treatment of cheyletiellosis in dogs. Loft KE; Willesen JL Vet Rec; 2007 Apr; 160(15):528-9. PubMed ID: 17435103 [No Abstract] [Full Text] [Related]
12. Monthly application of 10 per cent moxidectin and 2.5 per cent imidacloprid spot-on to prevent relapses in generalised demodicosis: a pilot study. Colombo S; Leone F; Vercelli A; Cornegliani L Vet Rec; 2012 Sep; 171(11):272. PubMed ID: 22791522 [TBL] [Abstract][Full Text] [Related]
13. Imidacloprid plus moxidectin topical solution for the prevention of heartworm disease (Dirofiloria immitis) in dogs. Arther RG; Bowman DD; Slone RL; Travis LE Parasitol Res; 2005 Oct; 97 Suppl 1():S76-S80. PubMed ID: 16228279 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of imidacloprid + moxidectin and selamectin topical solutions against the KS1 Ctenocephalides felis flea strain infesting cats. Dryden MW; Payne PA; Smith V; Hostetler J Parasit Vectors; 2011 Sep; 4():174. PubMed ID: 21914186 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sarolaner in the treatment of canine ear mite infestation caused by Otodectes cynotis: a non-inferiority study. Becskei C; Cuppens O; Mahabir SP Vet Dermatol; 2018 Apr; 29(2):100-e39. PubMed ID: 29392787 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of a combination of imidacloprid and moxidectin against parasites of reptiles and rodents: case reports. Mehlhorn H; Schmahl G; Mevissen I Parasitol Res; 2005 Oct; 97 Suppl 1():S97-S101. PubMed ID: 16228282 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of a novel oral isoxazoline, sarolaner (Simparica™), for the treatment of sarcoptic mange in dogs. Becskei C; De Bock F; Illambas J; Cherni JA; Fourie JJ; Lane M; Mahabir SP; Six RH Vet Parasitol; 2016 May; 222():56-61. PubMed ID: 26928658 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of selamectin against Sarcoptes scabiei on dogs and Otodectes cynotis on dogs and cats presented as veterinary patients. Six RH; Clemence RG; Thomas CA; Behan S; Boy MG; Watson P; Benchaoui HA; Clements PJ; Rowan TG; Jernigan AD Vet Parasitol; 2000 Aug; 91(3-4):291-309. PubMed ID: 10940530 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Adulticidal Efficacy of Imidacloprid 10 %/Moxidectin 2.5 % (w/v) Spot-on (Advocate®, Advantage® Multi) against Dirofilaria repens in Experimentally Infected Dogs. Petry G; Genchi M; Schmidt H; Schaper R; Lawrenz B; Genchi C Parasitol Res; 2015 Aug; 114 Suppl 1():S131-44. PubMed ID: 26152414 [TBL] [Abstract][Full Text] [Related]
20. Treatment of canine generalized demodicosis with a 'spot-on' formulation containing 10% moxidectin and 2.5% imidacloprid (Advocate, Bayer Healthcare). Mueller RS; Meyer D; Bensignor E; Sauter-Louis C Vet Dermatol; 2009 Oct; 20(5-6):441-6. PubMed ID: 20178482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]